Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice.

Da Hea Seo Young Ju Suh Yongin Cho Seong Hee Ahn Seong Ha Seo Seongbin Hong Eun Young Lee Young Ju Choi Eun Jig Lee So Hun Kim

Published in: Yonsei medical journal (2022)

Dapagliflozin, as an add-on or a switch therapy to lobeglitazone plus MFM, can be a suitable alternative for Korean patients with inadequately controlled T2DM. The combination therapy resulted in significant reductions in HbA1c levels, body weight, and blood pressure.

Keyphrases

combination therapy
body weight
blood pressure
clinical practice
hypertensive patients
heart rate
type diabetes
stem cells
glycemic control
metabolic syndrome
insulin resistance
mesenchymal stem cells
cell therapy